drugset / Trial / NCT00966940

Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

NCT00966940

Phase 4 Completed 51 enrolled Alcon Research
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.

Timeline

Start
2009-09
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Tafluprost Other / unclassified 0.0015 % Topical
Subject Travoprost Other / unclassified 0.004 % Topical

Indications